PharmaEssentia invests USD46M in Puerto Rico’s manufacturing facility

USA — Taiwanese biotech company PharmaEssentia has committed USD46 million to construct a cutting-edge manufacturing plant in Puerto Rico, marking a significant strategic move to expand production capabilities worldwide.

The facility will eventually manufacture Besremi, the company’s FDA-approved treatment for rare blood diseases, bolstering supply reliability and operational resilience for patients who depend on the medication.

Building manufacturing capacity outside Taiwan

The new manufacturing hub represents a core strategic priority for PharmaEssentia as the company works to strengthen its supply chain, increase production flexibility, and diversify its geographic footprint.

Ko-Chung Lin, the company’s founder and CEO, explained that establishing production in the United States—specifically in Puerto Rico—positions the firm to serve the U.S. market better while safeguarding against supply interruptions that could harm patients.

This expansion demonstrates the company’s commitment to securing long-term stability for its growing portfolio of rare disease treatments.

On February 9, PharmaEssentia announced the project as essential to securing cost efficiencies and providing the scalable manufacturing capacity needed to meet growing demand.

Initial construction will create nearly 100 jobs in the region, with opportunities for the workforce to expand significantly as the facility scales up operations in future phases.

The company plans to hire additional employees as production volumes increase over time.

 Redundancy and operational security

The 40,000-square-foot facility incorporates multiple safeguards to ensure continuous operations and uninterrupted product supply.

These protective measures include backup power generation and comprehensive infrastructure redundancies, all designed to minimize production disruptions and maintain consistent availability of Besremi for patients who depend on it.

Such careful planning reflects the company’s understanding that patients with rare blood diseases cannot tolerate supply shortages.

Expanding Besremi’s potential beyond Polycythemia Vera

In January, PharmaEssentia released encouraging findings from a clinical trial examining whether Besremi could treat essential thrombocythemia, another rare blood disorder distinct from its current approved indication.

The positive results prompted the company to begin discussions with regulatory authorities about broadening the drug’s therapeutic use to serve additional patient populations.

Recent data from the SURPASS-ET trial—a late-stage study comparing Besremi to anagrelide, a platelet-reducing medication commonly prescribed as a second-line therapy—demonstrated compelling outcomes.

Patients receiving Besremi showed sustained clinical improvements throughout the study and achieved a secondary goal: meaningful reductions in JAK2 V617F allelic burden, a genetic marker closely associated with the disease’s progression.

Essential thrombocythemia is a rare blood cancer typically caused by genetic mutations that prompt bone marrow to produce excessive platelets.

The FDA first granted Besremi approval in 2021, recognizing it as the first polycythemia vera treatment suitable for patients regardless of their prior treatment history and as the first interferon-based drug cleared for treating this particular disorder.